(NASDAQ: ZYME) Zymeworks's forecast annual revenue growth rate of 14.59% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 107.72%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.08%.
Zymeworks's revenue in 2025 is $93,384,000.On average, 9 Wall Street analysts forecast ZYME's revenue for 2025 to be $10,608,614,822, with the lowest ZYME revenue forecast at $7,665,184,120, and the highest ZYME revenue forecast at $14,648,166,853.  On average, 10 Wall Street analysts forecast ZYME's revenue for 2026 to be $10,579,347,755, with the lowest ZYME revenue forecast at $6,096,608,715, and the highest ZYME revenue forecast at $22,920,991,024.  
In 2027, ZYME is forecast to generate $9,604,475,702 in revenue, with the lowest revenue forecast at $2,526,723,420 and the highest revenue forecast at $15,712,233,776.